Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Q BioMed Inc. (QBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4516-0.0284 (-5.92%)
At close: 03:31PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4800
Open0.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4201 - 0.4516
52 Week Range0.2650 - 1.5900
Volume5,956
Avg. Volume72,750
Market Cap12.915M
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.3970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • PR Newswire

    Q BioMed Shows Significant Uptrend in Revenues in Year-End Update

    Q BioMed Inc. (OTCQB: QBIO), a commercial-stage biotech company, provides this update to shareholders with positive trend in revenues, advancement in pipeline assets and imminent uplisting to Nasdaq.

  • PR Newswire

    Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership

    Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, today announced it has engaged EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89, an FDA-approved cancer bone palliation radiotherapy.

  • PR Newswire

    Q BioMed Inc. Provides Shareholder Update

    Q BioMed Inc. (OTCQB: QBIO), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector is pleased to provide an update to its shareholders.

Advertisement
Advertisement